Nektar Therapeutics Announces Key Stock Grants Under Nasdaq Rule 5635(c)(4)
Nektar Therapeutics, a biotechnology firm renowned for its clinical-stage immunology treatments, recently announced significant employee equity incentives. On January 21, 2026, the Organization and Compensation Committee of its Board of Directors allocated non-qualified stock options to a newly-hired individual. This action falls under Nektar's 2025 Inducement Plan, aimed at attracting talent crucial for the company's growth while adhering to Nasdaq's listing requirements.
The granted stock options amount to 1,600 shares, valued at an exercise price of $36.92 per share, which totals to the company's closing stock value on the date of the grant. These shares are unique in that they come with an eight-year term and will vest over a structured period of four years. Employees will benefit from gradual allocation, beginning with 25% of the shares vesting by the end of the first year, followed by a monthly vesting of 1/48th of the shares for the subsequent three years, contingent on their continued employment with Nektar.
This inducement plan is designed exclusively for new employees who either were never employed by Nektar or who rejoin after a valid period of non-employment. The approach not only complies with Nasdaq Listing Rule 5635(c)(4) but also reinforces Nektar's commitment to cultivating a skilled workforce capable of driving the company's ambitious research and development agenda.
Nektar is primarily recognized for its pioneering therapeutic solutions targeting immunological dysfunctions inherent in autoimmune and chronic inflammatory conditions. Among these candidates is rezpegaldesleukin (REZPEG, or NKTR-358), a first-of-its-kind regulatory T cell stimulator currently undergoing evaluation in various Phase 2b clinical trials. Specifically, this innovative treatment is being explored for its efficacy in conditions such as atopic dermatitis, alopecia areata, and Type 1 diabetes mellitus.
In addition to rezpegaldesleukin, Nektar's robust pipeline features exciting developments including a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody, bispecific programs NKTR-0165 and NKTR-0166, and NKTR-422, a modified hematopoietic colony stimulating factor (CSF) protein. The company is also jointly conducting various clinical studies to assess NKTR-255, an IL-15 receptor agonist aimed at enhancing the immune system's capacity to combat cancers.
As Nektar Therapeutics continues to build a competent team geared toward groundbreaking treatments, this stock option grant exemplifies how they are strategically positioning themselves within the biotechnology sector and fostering an environment conducive to innovation and employee engagement.
Headquartered in San Francisco, California, Nektar remains committed to its mission of delivering novel therapies that can significantly alter patient outcomes in challenging health conditions. As the company progresses through clinical trials and advances its research, it invites stakeholders to stay informed about its developments by visiting its official website and connecting on platforms like LinkedIn. Nektar's journey, underscored by the latest stock option grants, highlights its potential to become a pivotal player in the biopharmaceutical landscape, employing strategies that not only attract talent but also showcase corporate compliance and responsibility.
The granted stock options amount to 1,600 shares, valued at an exercise price of $36.92 per share, which totals to the company's closing stock value on the date of the grant. These shares are unique in that they come with an eight-year term and will vest over a structured period of four years. Employees will benefit from gradual allocation, beginning with 25% of the shares vesting by the end of the first year, followed by a monthly vesting of 1/48th of the shares for the subsequent three years, contingent on their continued employment with Nektar.
This inducement plan is designed exclusively for new employees who either were never employed by Nektar or who rejoin after a valid period of non-employment. The approach not only complies with Nasdaq Listing Rule 5635(c)(4) but also reinforces Nektar's commitment to cultivating a skilled workforce capable of driving the company's ambitious research and development agenda.
Nektar is primarily recognized for its pioneering therapeutic solutions targeting immunological dysfunctions inherent in autoimmune and chronic inflammatory conditions. Among these candidates is rezpegaldesleukin (REZPEG, or NKTR-358), a first-of-its-kind regulatory T cell stimulator currently undergoing evaluation in various Phase 2b clinical trials. Specifically, this innovative treatment is being explored for its efficacy in conditions such as atopic dermatitis, alopecia areata, and Type 1 diabetes mellitus.
In addition to rezpegaldesleukin, Nektar's robust pipeline features exciting developments including a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody, bispecific programs NKTR-0165 and NKTR-0166, and NKTR-422, a modified hematopoietic colony stimulating factor (CSF) protein. The company is also jointly conducting various clinical studies to assess NKTR-255, an IL-15 receptor agonist aimed at enhancing the immune system's capacity to combat cancers.
As Nektar Therapeutics continues to build a competent team geared toward groundbreaking treatments, this stock option grant exemplifies how they are strategically positioning themselves within the biotechnology sector and fostering an environment conducive to innovation and employee engagement.
Headquartered in San Francisco, California, Nektar remains committed to its mission of delivering novel therapies that can significantly alter patient outcomes in challenging health conditions. As the company progresses through clinical trials and advances its research, it invites stakeholders to stay informed about its developments by visiting its official website and connecting on platforms like LinkedIn. Nektar's journey, underscored by the latest stock option grants, highlights its potential to become a pivotal player in the biopharmaceutical landscape, employing strategies that not only attract talent but also showcase corporate compliance and responsibility.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.